What does this research mean for the field?

In patients with non-small cell lung cancer presenting with synchronous brain metastases, stereotactic radiosurgery and neurosurgical resection offer a survival advantage when combined with TKIs, immunotherapy, or radical treatment, whereas whole brain radiotherapy and chemotherapy have limited impact. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate survival outcomes and clinical characteristics in patients presenting with non-small cell lung cancer (NSCLC) and synchronous brain metastases across diverse systemic and intracranial treatments.

August 29, 2026Neuro-Oncology

94 Outcome of patients with metastatic lung cancer presenting with synchronous brain metastases – A single centre; 5 year retrospective analysis

View Full Paper

Ask AI

Bookmark

To evaluate survival outcomes and clinical characteristics in patients presenting with non-small cell lung cancer (NSCLC) and synchronous brain metastases across diverse systemic and intracranial treatments.
Conducted a single-center retrospective analysis of N=200 patients presenting with NSCLC and synchronous brain metastases between 2017 and 2022.
Assessed demographic features, tumor histology, programmed death-ligand 1 (PD-L1) expression, targetable genetic alterations, primary cancer regimens, and intracranial treatment modalities.
Median overall survival across the entire cohort was 6.7 months, with adenocarcinoma representing the predominant histology (82%).
Median overall survival differed markedly by primary systemic therapy: 27.0 months for tyrosine kinase inhibitors, 15.4 months for radical thoracic therapy, 14.7 months for immunotherapy, 7.6 months for chemotherapy, and 2.9 months for best supportive care.
Median overall survival varied by intracranial approach: 34.0 months for multimodality care, 14.7 months for neurosurgical resection, 13.9 months for stereotactic radiosurgery, 6.2 months for whole brain radiotherapy, and 4.8 months for best supportive care.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective study reveals divergent survival outcomes across treatment modalities in lung cancer with synchronous brain metastases, highlighting benefits of targeted therapies and local brain...

Cite This Study

Hebbes et al. (2026) studied this question.

synapsesocial.com/papers/6a92996e8e5d7d1fc0c11602 https://doi.org/10.1093/neuonc/noag172.032

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study reveals divergent survival outcomes across treatment modalities in lung cancer with synchronous brain metastases, highlighting benefits of targeted therapies and local brain...

94 Outcome of patients with metastatic lung cancer presenting with synchronous brain metastases – A single centre; 5 year retrospective analysis

Key Points

Discussion

Implication

Cite This Study

94 Outcome of patients with metastatic lung cancer presenting with synchronous brain metastases – A single centre; 5 year retrospective analysis

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider